← Back to Screener
Clearmind Medicine Inc. Common Shares (CMND)
Price$0.83
Favorite Metrics
Price vs S&P 500 (26W)-102.31%
Price vs S&P 500 (4W)-9.74%
Market Capitalization$1.74M
All Metrics
Book Value / Share (Quarterly)$7.92
P/TBV (Annual)1.88x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-35.16
Price vs S&P 500 (YTD)-66.73%
EPS (TTM)$-53.93
10-Day Avg Trading Volume2.54M
EPS Excl Extra (TTM)$-53.93
EPS (Annual)$-30.35
ROI (Annual)-166.25%
Cash / Share (Quarterly)$26.00
ROA (Last FY)-72.42%
EBITD / Share (TTM)$-60.79
ROE (5Y Avg)-249.70%
Cash Flow / Share (Annual)$-45.57
P/B Ratio1.64x
P/B Ratio (Quarterly)5.05x
Net Interest Coverage (TTM)-2.74x
ROA (TTM)-70.45%
EPS Incl Extra (Annual)$-30.35
Current Ratio (Annual)1.72x
Quick Ratio (Quarterly)1.28x
3-Month Avg Trading Volume0.51M
52-Week Price Return-98.24%
Tangible BV / Share (Quarterly)$7.18
52-Week High$52.40
EPS Excl Extra (Annual)$-30.35
26-Week Price Return-98.32%
Quick Ratio (Annual)1.71x
13-Week Price Return-69.91%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)1.32x
Enterprise Value$-1.724
Cash / Share (Annual)$64.36
3-Month Return Std Dev144.33%
ROE (Last FY)-169.09%
Net Interest Coverage (Annual)-19.64x
EPS Basic Excl Extra (Annual)$-30.35
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-53.93
Receivables Turnover (Annual)0.00x
ROI (TTM)-170.64%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$28.13
Price vs S&P 500 (52W)-128.07%
Year-to-Date Return-64.09%
5-Day Price Return-45.83%
EPS Normalized (Annual)$-30.35
ROA (5Y Avg)-233.83%
Month-to-Date Return-37.50%
EBITD / Share (Annual)$-44.44
ROI (5Y Avg)-249.14%
EPS Basic Excl Extra (TTM)$-53.93
P/TBV (Quarterly)5.57x
P/B Ratio (Annual)1.81x
Book Value / Share (Annual)$29.14
Price vs S&P 500 (13W)-70.59%
Beta21.53x
Revenue / Share (TTM)$0.00
ROE (TTM)-173.63%
52-Week Low$0.59
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CMNDClearmind Medicine Inc. Common Shares | — | — | — | — | $0.83 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Clearmind Medicine is a clinical-stage biopharmaceutical company developing MEAI, a novel psychedelic compound, for treating mental health disorders including alcohol use disorder, binge drinking, and eating disorders. The company is advancing its lead candidate through Phase I/IIa clinical trials with operations based in Israel.